EP3773715
Mírikísúmab til meðhöndlunar á sáraristilbólgu
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
28.3.2019EP published:
8.5.2024EP application number:
19722256.5
EP translation filed:
10.6.2024Grant published:
15.7.2024EPO information:
European Patent Register
Max expiry date:
27.3.2039Expiry date:
27.3.2027Next due date:
31.3.2027
Title in English:
MIRIKIZUMAB IN THE TREATMENT OF ULCERATIVE COLITISLanguage of the patent:
English
Timeline
Today
28.3.2019EP application
8.5.2024EP Publication
10.6.2024Translation submitted
15.7.2024Registration published
27.3.2027Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285, US
Inventor
Name:
CANAVAN, James BenedictAddress:
Indianapolis, Indiana 46206-6288, US
Name:
FRIEDRICH, Stuart WilliamAddress:
Indianapolis, Indiana 46206-6288, US
Name:
KRUEGER, Kathryn AnnAddress:
Indianapolis, Indiana 46206-6288, US
Name:
MILCH, CatherineAddress:
Indianapolis, Indiana 46206-6288, US
Name:
TUTTLE, Jay LawrenceAddress:
Indianapolis, Indiana 46206-6288, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862650314 PDate:
30.3.2018Country:
US
Classification
Categories:
A61K 39/395, C07K 16/24, A61P 1/04
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 12.3.2025
Expires: 27.3.2026
Payer: Árnason Faktor ehf.
Number: 8
Paid: 20.3.2026
Expires: 27.3.2027
Payer: Árnason Faktor ehf.